Top 5 Safest Stocks To Own Right Now

Numis Securities cut shares of Safestore (LON:SAFE) to a hold rating in a report published on Thursday morning.

Several other research analysts also recently issued reports on the stock. Liberum Capital reissued a buy rating and set a GBX 560 ($7.46) price objective on shares of Safestore in a research report on Thursday, February 22nd. Peel Hunt reissued a hold rating on shares of Safestore in a research report on Thursday, April 5th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has an average rating of Buy and an average target price of GBX 540.83 ($7.20).

Get Safestore alerts:

Safestore opened at GBX 556.50 ($7.41) on Thursday, MarketBeat Ratings reports. Safestore has a 1-year low of GBX 360 ($4.79) and a 1-year high of GBX 528 ($7.03).

Top 5 Safest Stocks To Own Right Now: First Financial Northwest Inc.(FFNW)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on First Financial Northwest (FFNW)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on First Financial Northwest (FFNW)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Safest Stocks To Own Right Now: Coinstar Inc.(CSTR)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Capstar Financial (NASDAQ: CSTR) and Mercantile Bank (NASDAQ:MBWM) are both small-cap finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.

  • [By Joseph Griffin]

    Shares of Capstar Financial Holdings Inc (NASDAQ:CSTR) have been assigned an average rating of “Hold” from the five research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $19.75.

Top 5 Safest Stocks To Own Right Now: Celgene Corporation(CELG)

Advisors’ Opinion:

  • [By Motley Fool Staff]

    Stock No. 1: The first one up, alphabetically, is Celgene (NASDAQ:CELG). The ticker symbol is CELG. Celgene, two years ago, was at $101 a share. Celgene, as of Monday’s market close was down to $84.57. So, not such a great stock pick of mine. Celgene down 16%. The market up 30%. So, we’re going to have to log a minus 46% to start this review of my stocks from five years ago, as Celgene has dropped a little and the market, as we’ve already established, has done quite well.

  • [By ]

    Cramer was bearish on Xilinx (XLNX) , Celgene (CELG) , Exelixis (EXEL) , Moneygram (MGI) , Monster Beverage (MNST) , SunCoke Energy Partners (SXCP) and Mattel (MAT) .

  • [By Logan Wallace]

    Celgene (NASDAQ:CELG) announced that its Board of Directors has approved a stock repurchase program, which allows the company to buyback $3.00 billion in shares on Thursday, May 24th. This buyback authorization allows the biopharmaceutical company to buy up to 5.4% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

  • [By Keith Speights]

    There’s room for debate, of course. But in my view, three deals especially stand out. Here’s why I rank Celgene’s (NASDAQ:CELG) buyout of Juno Therapeutics, Novartis’ (NYSE:NVS) acquisition of AveXis, and Roche’s (NASDAQOTH:RHHBY) purchase of Foundation Medicine (NASDAQ:FMI) as the best biotech acquisitions of 2018 (so far).

  • [By Paul Ausick]

    Celgene Corp. (NASDAQ: CELG) dropped about 1.8% Friday to post a new 52-week low of $78.51. Shares closed at $79.98 on Thursday and the stock’s 52-week high is $147.17. Volume of around 5.4 million shares was about 20% below the daily average. The company was one of several named Thursday in an FDA report of drugmakers who may be illegally blocking delaying access to cheaper generic copies of brand-name drugs.

  • [By Ethan Ryder]

    Sumitomo Mitsui Trust Holdings Inc. increased its holdings in Celgene (NASDAQ:CELG) by 3.9% during the first quarter, HoldingsChannel.com reports. The fund owned 2,379,884 shares of the biopharmaceutical company’s stock after buying an additional 89,641 shares during the period. Sumitomo Mitsui Trust Holdings Inc.’s holdings in Celgene were worth $212,309,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Top 5 Safest Stocks To Own Right Now: PAREXEL International Corporation(PRXL)

Advisors’ Opinion:

  • [By Logan Wallace]

    News headlines about PAREXEL International (NASDAQ:PRXL) have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. PAREXEL International earned a news impact score of 0.18 on Accern’s scale. Accern also gave press coverage about the medical research company an impact score of 49.4978250148766 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Top 5 Safest Stocks To Own Right Now: ZIOPHARM Oncology Inc(ZIOP)

Advisors’ Opinion:

  • [By Keith Speights]

    Over the last 12 months, bluebird bio (NASDAQ:BLUE) stock has more than doubled. During the same period, Ziopharm Oncology’s (NASDAQ:ZIOP) share price has tumbled over 30%. That’s the past, though. Which of these two clinical-stage biotech stocks is the better pick for investors now?

  • [By Keith Speights]

    If you like putting money into the beaten-down stocks of clinical-stage biotechs, Ziopharm Oncology (NASDAQ:ZIOP) and Celldex Therapeutics (NASDAQ:CLDX) might warrant a look. Ziopharm’s share price has dropped more than 25% so far in 2018, while Celldex stock has plunged more than 80%.

  • [By Paul Ausick]

    Ziopharm Oncology Inc. (NASDAQ: ZIOP) dropped more than 10% Tuesday to post a 52-week low of $3.77 after closing at $4.20 on Monday. The 52-week high is $7.88. Volume was around 3.7 million, more than double the daily average. The company reported Tuesday on progress of two platforms it is developing and investors did not like what they heard.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Stellar Biotechnologies, Inc. (NASDAQ: SBOT) fell 42 percent to $2.25 in pre-market trading after dropping 31.45 percent on Thursday. Stellar Biotechnologies priced 2.075 million units at price of $2.65 per unit.
    Symantec Corporation (NASDAQ: SYMC) shares fell 25.2 percent to $21.82 in pre-market trading. Symantec reported better-than-expected earnings for its fourth quarter, but issued weak second-quarter guidance.
    AGM Group Holdings Inc. (NASDAQ: AGMH) shares fell 9.5 percent to $10 in pre-market trading after surging 7.79 percent on Thursday.
    ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) fell 8.9 percent to $4.11 in pre-market trading after the company posted wider-than-expected Q1 loss.
    Redfin Corporation (NASDAQ: RDFN) fell 8.6 percent to $21.00 in pre-market trading after reporting Q1 results.
    Geron Corporation (NASDAQ: GERN) fell 8.3 percent to $3.33 in pre-market trading. Geron posted a Q1 loss of $0.04 per share.
    Talend S.A. (NASDAQ: TLND) shares fell 6 percent to $56 in pre-market trading after reporting Q1 results.
    Flotek Industries, Inc. (NYSE: FTK) fell 5.4 percent to $3.54 in pre-market trading after dropping 2.35 percent on Thursday.
    Halozyme Therapeutics, Inc. (NASDAQ: HALO) fell 5.1 percent to $18.95 in pre-market trading after reporting Q1 results.
    Yelp Inc. (NYSE: YELP) shares fell 4.9 percent to $45.40 in pre-market trading. Yelp reported stronger-than-expected results for its first quarter on Thursday.
    Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shares fell 3.3 percent to $7.50 in pre-market trading after dropping 4.32 percent on Thursday

  • [By Keith Speights]

    Ziopharm Oncology Inc. (NASDAQ:ZIOP) shareholders have been on a roller coaster ride this year. The stock soared 16% in May, but the ride promptly went downhill in June, with the biotech’s share price dropping more than 10%. The first four months of 2018 featured more of the same up-and-down action.

  • [By Todd Campbell]

    After disclosing that the Food and Drug Administration is asking for more information before signing off on a phase 1 study of its “Sleeping Beauty” CAR-T for leukemia and lymphoma, shares in Ziopharm Oncology (NASDAQ:ZIOP) were tumbling 17.7% at 3 p.m. EDT today.

Leave a Reply

Your email address will not be published. Required fields are marked *